Targeted therapies are being developed to target NSCLC harboring METex14 skipping alterations or MET amplification, and available information indicates that both MET alterations are predictive markers in NSCLC, conferring sensitivity to MET inhibition [1,2,5]. Here, MET is linked to non-small cell lung carcinoma.